MALIGNANT MELANOMA

This large, completed Phase 3 trial tested if adding the drug lenvatinib to the standard immunotherapy pembrolizumab works better for adults with advanced melanoma who haven't had prior drug treatment. The goal was to see if the two-drug combination helps patients live longer and…

This early-stage study tested the safety of combining two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and see how the body processes …

This completed Phase 3 trial tested whether adding the drug lenvatinib to the immunotherapy pembrolizumab works better than pembrolizumab alone for Chinese patients with advanced melanoma that has spread. The study involved 131 participants who had not received prior drug treatme…

This study aimed to understand a specific eye side effect that can occur when melanoma patients take a common combination of targeted drugs (BRAF and MEK inhibitors). Researchers closely monitored the vision and eye health of 14 patients during and after their cancer treatment to…

This study aimed to find a better way to predict which patients with advanced skin cancer (metastatic melanoma) would respond well to a common type of immunotherapy. Researchers measured levels of a protein called interferon-gamma in patients' tumors and blood, and also looked at…

This study looked at how certain melanoma cancer drugs affect patients' eyes and vision. Researchers followed 30 adults taking BRAF/MEK inhibitor combinations to understand how often these drugs cause retinal changes called MEKAR. Participants received regular eye exams before, d…